Latest news

• Gilead, Galapagos JAK inhibitor clears phase II test

  DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.

• Another R&D flop for Incyte, but Jakafi keeps delivering

  Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)

• AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

  be an under-estimate given that a third JAK inhibitor - Eli Lilly and Incyre’s Olumiant (baricitinib) - has been dogged by regulatory problems.

• FDA panel undermines Lilly and Incyte’s baricitinib hopes

  FDA panel undermines Lilly and Incyte’ s baricitinib hopes. Mixed review doesn’t bode well in competitive market. ... baricitinib’s potential to cause side effects such as pulmonary embolism and venous thromboembolism.